<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248208</url>
  </required_header>
  <id_info>
    <org_study_id>357349</org_study_id>
    <nct_id>NCT01248208</nct_id>
  </id_info>
  <brief_title>FluMist in Egg Allergic Patients</brief_title>
  <acronym>FluEMIST</acronym>
  <official_title>Flu Vaccine in Egg-allergic Patients Minimizing Injections Safety Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scripps Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the growing public health concerns of seasonal influenza and H1N1 in the United States,&#xD;
      the primary means by which this can be addressed is with prevention, namely, vaccination&#xD;
      against the influenza virus. The only individuals not able to receive this vaccination in the&#xD;
      primary care provider's office are those patients with egg allergies and, in rare&#xD;
      circumstances, individuals with allergies to other components of the vaccine. Current&#xD;
      guidelines allow for the administration of the influenza vaccine to patients with egg allergy&#xD;
      using vaccines with low egg protein (ovalbumin) content or by using skin testing followed by&#xD;
      a 5-dose desensitization protocol. Since this is impractical to perform in the primary care&#xD;
      office and cumbersome for allergists, many egg-allergic patients simply do not receive the&#xD;
      influenza vaccine, leaving them more vulnerable to the disease and more likely to become a&#xD;
      source of contagion.&#xD;
&#xD;
      Several studies have suggested that influenza vaccination using a 1-2 dose protocol may be&#xD;
      safe. This fact is due in large part to the low ovalbumin (egg protein) content in modern&#xD;
      influenza vaccines. All studies of influenza vaccination in egg-allergic patients have been&#xD;
      done using intramuscular trivalent inactivated influenza vaccine (TIV). However, the&#xD;
      trivalent live-attenuated, cold-adapted influenza vaccine (LAIV), which is delivered&#xD;
      intranasally, has a lower published ovalbumin content than the injectable vaccines,&#xD;
      suggesting that it may also be well-tolerated by egg-allergic patients. According to several&#xD;
      studies, LAIV may be more efficacious than TIV in children.&#xD;
&#xD;
      It is the goal of the investigators to evaluate the safety of immunizing egg-allergic&#xD;
      individuals with the LAIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with egg allergy will be recruited into the study. Since the trivalent&#xD;
      live-attenuated, cold-adapted influenza vaccine (LAIV) contains the lowest amount of egg&#xD;
      protein of all available influenza vaccines on the market, those who are eligible to receive&#xD;
      the intranasal formulation (LAIV group) (ie age 2-49y, not asthmatic) will receive FluMist;&#xD;
      others will receive the intramuscular injection in a single dose without skin testing (TIV&#xD;
      group). All subjects will be monitored for 30 minutes post-vaccine for any signs/symptoms of&#xD;
      an immediate allergic reaction. Subjects will also be followed-up by phone 24-48 hours after&#xD;
      administration to assess for any delayed allergic reaction. Data will be collected for one&#xD;
      entire Influenza season (2010-2011).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 1, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the safety of LAIV in egg-allergic patients receiving the LAIV.</measure>
    <time_frame>within 48 hours after vaccine administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the safety of a single, full-strength dose of TIV in egg allergic patients.</measure>
    <time_frame>Within 48 hours of vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Egg Allergy</condition>
  <condition>Eligible for Vaccination Against Influenza</condition>
  <arm_group>
    <arm_group_label>FluMist (LAIV) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FluMist influenza vaccine 0.2 mL intranasal vaccine once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flu shot (TIV) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients 6 months to 2 yrs or &gt; 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:&#xD;
wheezing in the past 12 months&#xD;
use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months&#xD;
emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist intranasal influenza vaccine</intervention_name>
    <description>FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.</description>
    <arm_group_label>FluMist (LAIV) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramuscular influenza injection (&quot;flu shot&quot;)</intervention_name>
    <description>Subjects &lt; 2 years or &gt; 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.&#xD;
Age 6-36 months: 0.25 mL IM x 1; Age &gt;36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose.</description>
    <arm_group_label>Flu shot (TIV) group</arm_group_label>
    <other_name>Fluzone (approved for children down to 6 months)</other_name>
    <other_name>Fluvirin (age 4y and older)</other_name>
    <other_name>Agriflu (age 18y and older)</other_name>
    <other_name>Fluarix (age 3y and older)</other_name>
    <other_name>FluLaval (age 18y and older)</other_name>
    <other_name>Afluria (age 9y and older)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 6 months&#xD;
&#xD;
          -  Clinical history of allergic symptoms (hives, swelling, vomiting, respiratory&#xD;
             problems, low blood pressure) within 2 hours after ingestion of egg OR Eczema/atopic&#xD;
             dermatitis worsened by egg exposure&#xD;
&#xD;
          -  Confirmation of clinical history by positive egg skin prick test or serum egg-specific&#xD;
             IgE or a positive oral food challenge. [The &gt;95% positive predictive values of egg&#xD;
             serum IgE in subjects &gt;2 years old with atopic dermatitis is 6 kU/L or greater. In&#xD;
             subjects &gt;2 years old without atopic dermatitis, the value is 7 kU/L or greater. In&#xD;
             subjects less than 2 years old, the value is 2 kU/L or greater.]&#xD;
&#xD;
          -  FluMist (LAIV) cohort: Patients age 2-49 years WITHOUT a history of asthma symptoms or&#xD;
             treatment within the past 12 months will receive intranasal FluMist.&#xD;
&#xD;
          -  Flu Shot (TIV) Intramuscular influenza vaccine cohort: Patients 6 months to 2 yrs or &gt;&#xD;
             49 years or WITH a history of asthma symptoms / treatment within the past 12 months.&#xD;
             History/Treatment of asthma in the past 12 months is defined as follows:&#xD;
&#xD;
               1. wheezing in the past 12 months&#xD;
&#xD;
               2. use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist&#xD;
                  (LABA), or oral steroid in the past 12 months&#xD;
&#xD;
               3. emergency room or acute care visit or hospitalization for asthma or wheezing in&#xD;
                  the past 12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who potentially have outgrown their egg allergy (no allergic reaction with&#xD;
             ingestion of whole egg in the past 18 months and an egg serum specific IgE level â‰¤2&#xD;
             kU/L).&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current moderate to severe illness with a fever.&#xD;
&#xD;
          -  Allergy to other components of the vaccine - gentamicin, gelatin, arginine, thimerosal&#xD;
             - or a history of a previous allergic reaction to the influenza vaccine.&#xD;
&#xD;
          -  Abnormal Vital Signs.&#xD;
&#xD;
          -  History of Guillain-Barre' Syndrome (GBS).&#xD;
&#xD;
          -  HIV/AIDS or another disease that affects the immune system, or cancer.&#xD;
&#xD;
          -  Long term health problems that are contraindicated for the LAIV or TIV.&#xD;
&#xD;
          -  Receipt of a live viral vaccine within the month prior (e.g. FluMist, MMR, yellow&#xD;
             fever, chicken pox, rotavirus, smallpox).&#xD;
&#xD;
          -  Current use of any prescription medicine (e.g. antiviral) to prevent or treat&#xD;
             influenza. (only excludes use of LAIV, may still receive TIV)&#xD;
&#xD;
          -  Concurrent use of aspirin or aspirin-containing therapy in children and adolescents&#xD;
             (2-18 years of age)(only excludes use of LAIV, may still receive TIV)&#xD;
&#xD;
          -  Living with or having close contact with someone whose immune system is severely&#xD;
             compromised (e.g. transplant recipient). (only excludes use of LAIV, may still receive&#xD;
             TIV) Breastfeeding mothers may still receive either LAIV or TIV.&#xD;
&#xD;
          -  The following medications can interfere with signs of an allergic reaction or&#xD;
             complicate the treatment of an allergic reaction and should be discontinued as&#xD;
             outlined below:&#xD;
&#xD;
               1. H1 antihistamines or doxepin should be discontinued for 7 days, and&#xD;
                  diphenhydramine for 72 hrs prior.&#xD;
&#xD;
               2. H2 antihistamines should be discontinued for 24 hrs prior.&#xD;
&#xD;
               3. Tricyclic antidepressants should be discontinued, after consultation with the&#xD;
                  prescribing physician, for 6 weeks prior.&#xD;
&#xD;
               4. Beta blockers should be discontinued, after consultation with the prescribing&#xD;
                  physician, for 24 hours prior.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Laubach, MD</last_name>
    <role>Study Director</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/flu/index.htm</url>
    <description>CDC Information on Seasonal Influenza</description>
  </link>
  <link>
    <url>http://www.foodallergy.org</url>
    <description>Food Allergy and Anaphylaxis Network</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Walter Reed Army Medical Center</investigator_affiliation>
    <investigator_full_name>Susan Laubach</investigator_full_name>
    <investigator_title>Allergy &amp; Immunology faculty</investigator_title>
  </responsible_party>
  <keyword>egg allergy</keyword>
  <keyword>influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Egg Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

